TTrialPathMatch Me to Trials
← Back to trials
RecruitingAtypical Hemolytic-Uremic Syndrome

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Eligible age

All ages

Accepts

All genders

Locations

9 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

Sponsor: Alexion Pharmaceuticals, Inc.

You may qualify if…

  • ✓ Male or female patients of any age, including minors, who have been diagnosed with aHUS
  • ✓ Patients with or without an identified complement pathogenic variant or anti-complement factor antibody
  • ✓ Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent \[if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)\].
  • ✓ ADAMTS13 \> 5%, if performed.

You may not qualify if…

  • ✕ Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli (STEC).
  • ✕ Unable to give written informed consent. Patient or patient's parent/legal guardian unable to give written informed consent. Patient (if minor) unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees \[IRB/IEC\]).

Where it's recruiting

Colorado

Aurora

District of Columbia

Washington D.C.

Florida

Gainesville

Georgia

Atlanta

Illinois

Chicago

Missouri

St Louis

North Carolina

Winston-Salem

Ohio

Columbus

Source: ClinicalTrials.gov · NCT01522183 · last updated 2025-09-16